Kiadis collaborates with premier Dutch institutions to apply K-NK-cell technology for the development of a novel COVID-19 therapy
August 17, 2020 01:00 ET
|
Kiadis Pharma N.V.
Initiates new COVID-19 research and development program (K-NK-ID101)Expands the application of Kiadis’ K-NK technology into infectious diseasesAnnounces collaboration with five premier Dutch...
Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi
July 22, 2020 01:00 ET
|
Kiadis Pharma N.V.
CD38KO NK cell therapy has the potential to maximize the efficacy of anti-CD38 against multiple myeloma Amsterdam, The Netherlands, July 22, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)...
Kiadis appoints Ray Barlow, Ph.D. as Chief Business Officer and Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management Team
July 13, 2020 01:00 ET
|
Kiadis Pharma N.V.
Senior executives with extensive biotechnology and pharmaceutical industry, science, innovation and business development experience Bringing unique capabilities to unlock broad potential of Kiadis...
Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties
July 08, 2020 01:00 ET
|
Kiadis Pharma N.V.
Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with...
Kiadis to present at the Solebury Trout & Venrock EU Virtual Summer Event
July 02, 2020 01:30 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, July 2, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that...
Kiadis Announces Results of Annual General Meeting of Shareholders
June 25, 2020 11:50 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, June 25, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that at its...
Kiadis announces first patient enrolled in clinical study conducted at The Ohio State University in R/R AML with off-the-shelf K-NK cells from universal donors as part of its K-NK003 program
June 25, 2020 01:00 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, June 25, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, and The Ohio State...
Kiadis to present at the Virtual European Biotech Investor Day 2020
June 17, 2020 01:30 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, June 17, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that...
Kiadis announces new data demonstrating that K-NK cells persist and proliferate in vivo and that K-NK cells used across past and future trials have the same unique hyperfunctional phenotype
June 12, 2020 02:30 ET
|
Kiadis Pharma N.V.
3 presentations related to Kiadis’ K-NK cell therapy platform will be presented today at the 25th Congress of the European Hematology Association An oral presentation (abstract #S284) shows clinical...
Kiadis announces new data related to its K-NK cell therapy platform presented today at the ASCO 2020 Virtual Annual Meeting
May 29, 2020 08:05 ET
|
Kiadis Pharma N.V.
A poster presentation (abstract 3025) demonstrates results of multiple FC21-NK infusions in R/R AML patients with CNS disease, treated in an investigator-initiated Phase I/II studyAn abstract accepted...